Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Do ingredients make the difference?: finding the best cocktail of an anticoagulant with antiplatelets.

Sinnaeve PR, Van de Werf F.

Circulation. 2013 Feb 5;127(5):566-8. doi: 10.1161/CIRCULATIONAHA.112.155929. Epub 2012 Dec 27. No abstract available.

2.

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.

Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S.

Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.

3.

Warfarin: is the end nigh? Please?

Neilson RF.

J R Coll Physicians Edinb. 2010 Sep;40(3):222-3. doi: 10.4997/JRCPE.2010.322. No abstract available.

PMID:
21127766
4.

Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.

Belavic JM.

Nurse Pract. 2011 Sep;36(9):6-7. doi: 10.1097/01.NPR.0000403296.82092.fb. No abstract available.

PMID:
21857210
5.

Atrial fibrillation: A promising new anticoagulant for stroke prevention.

Spinler SA.

Nat Rev Cardiol. 2010 Jan;7(1):10-1. doi: 10.1038/nrcardio.2009.220. No abstract available.

PMID:
20019756
6.
7.
8.

Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.

Paikin JS, Haroun MJ, Eikelboom JW.

Expert Rev Cardiovasc Ther. 2011 Mar;9(3):279-86. doi: 10.1586/erc.11.21.

PMID:
21438804
9.

Should dabigatran replace warfarin for stroke prevention in AF?

[No authors listed]

Drug Ther Bull. 2011 Oct;49(10):114-7. doi: 10.1136/dtb.2011.02.0060. Review.

PMID:
21994438
10.

Dabigatran v warfarin. Compare with higher standard.

Edwards D.

BMJ. 2010 Oct 26;341:c5984. doi: 10.1136/bmj.c5984. No abstract available.

PMID:
20978048
11.

Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.

Khoo CW, Lip GY.

Expert Opin Pharmacother. 2010 Mar;11(4):685-7. doi: 10.1517/14656560903530691.

PMID:
20105114
12.

Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.

Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM.

Thromb Haemost. 2010 Dec;104(6):1106-15. doi: 10.1160/TH10-10-0642. Epub 2010 Oct 21.

PMID:
20967400
13.

Another novel oral anticoagulant matches warfarin.

Mitka M.

JAMA. 2014 Jan 15;311(3):233-4. doi: 10.1001/jama.2013.284833. No abstract available.

PMID:
24430308
14.

[Dabigatran versus Warfarin in patients with atrial fibrillation. Results of the RE-LY study].

Liakishev AA.

Kardiologiia. 2009;49(10):75-6. Russian. No abstract available.

PMID:
19845524
15.

Dabigatran versus warfarin in patients with atrial fibrillation.

Tomoda H.

N Engl J Med. 2009 Dec 31;361(27):2671-2; author reply 2674-5. No abstract available.

PMID:
20050382
16.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
17.

Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation.

Schwartz NE, Albers GW.

Stroke. 2010 Jun;41(6):1307-9. doi: 10.1161/STROKEAHA.110.584557. Epub 2010 Apr 15. Review. No abstract available.

18.

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ.

Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Review.

PMID:
23322134
19.

[New drug in atrial fibrillation--how does it function in regular health care?].

Holmström M, Johnsson H, Lärfars G, Malmström R, Hjemdahl P.

Lakartidningen. 2009 Nov 4-12;106(45):3019-20. Swedish. No abstract available.

PMID:
19998831
20.

Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.

Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S; RE-LY Steering Committee and Investigators.

Circulation. 2010 Nov 30;122(22):2246-53. doi: 10.1161/CIRCULATIONAHA.110.973735.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk